We provide you with 20 years of free, institutional-grade data for ELYM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ELYM. Explore the full financial landscape of ELYM stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Morisset Valerie | Derivatives Exercise | 17,847 | 2024-04-08 | ||
| Morisset Valerie | Derivatives Exercise | 20,728 | 2024-03-04 | ||
| Morisset Valerie | Derivatives Exercise | 316,410 | 2023-03-14 | ||
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 195,218 | $12.5 | 2021-08-16 | |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 3,004,782 | $12.5 | 2021-08-16 | |
| AI ETI LLC | Open Market Purchase | 800,000 | $12.5 | 2021-08-16 | |
| Morisset Valerie | Initial | 2021-08-09 | |||
| Rosenberg Adam Joseph | Initial | 2021-08-09 |
The information provided in this report about ELYM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Eliem Therapeutics, Inc(NASDAQ:ELYM) 
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The compan...
Website: http://www.eliemtx.com
Founded: 2018
CEO: Bob Azelby
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends